2021 Fiscal Year Final Research Report
Development of a Novel Treatment for Scleroderma by Regulation of Cytokine-Producing B Cells
Project/Area Number |
19K08768
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 53050:Dermatology-related
|
Research Institution | Kanazawa University |
Principal Investigator |
|
Project Period (FY) |
2019-04-01 – 2022-03-31
|
Keywords | 全身性強皮症 / Regulatory B細胞 / Effector B細胞 / IL-6 / IL-10 |
Outline of Final Research Achievements |
It is known that B cells are strongly involved in the pathogenesis of systemic scleroderma through autoantibody production. This research plan aims to develop a selective B cell inhibitory therapy that inhibits only effector B cells. B cells were extracted from mouse spleens and subjected to microarray analysis in three groups: anti-CD40 antibody stimulation, LPS stimulation alone, and LPS+anti-CD40 antibody stimulation. On the other hand, in the anti-CD40 antibody-stimulated group, in which IL-6 was low, gene expression of the A and B genes was low. These results suggest that the A gene may regulate IL-6 production.
|
Free Research Field |
皮膚科学
|
Academic Significance and Societal Importance of the Research Achievements |
本研究では、自己免疫疾患におけるB細胞を標的とした新規治療法の開発を目指しており、創造性に富む研究テーマである。本研究により、A遺伝子がIL-6産生を制御している可能性が示唆され、この結果を応用すれば、すべてのB細胞を除去するのではなく、Effector B細胞のみを除去する選択的B細胞阻害去療法の開発につながる重要な発見である。
|